The incorporation of the anti-PD-1 monoclonal antibody pembrolizumab into chemotherapy, whether combined with bevacizumab or not, demonstrated notable enhancements in OS and PFS for patients suffering from recurrent or metastatic cervical cancer, in contrast to the regimen involving placebo and chemotherapy. This evidence concerns the gene PDCD1 and cervical carcinoma.